9月3日，富时罗素宣布对富时中国50指数、富时中国A50指数等的季度审核变更，纳入百济神州、药明 康德等A股，剔除中国核电等A股。该变更将于2025年9月19日星期五收盘后（即9月22日星期一）生 效。 点评：作为全球知名的指数编制公司，富时罗素的纳入标准较为严格，此次调整体现了A股公司在全球 资本市场中的重要性不断提升，以及外资对中国创新药板块的持续关注和参与。 NO.3 大冢制药IgA肾病靶向药物上市申请获受理 每经记者｜林姿辰 每经编辑｜张益铭 丨2025年9月4日 星期四丨 NO.1 永安药业实际控制人、董事长解除留置 9月3日，永安药业发布公告称，公司收到实际控制人、董事长陈勇家属的通知，其收到鹤峰县监察委员 会出具的《解除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。目前，陈勇已能正常 履行公司董事长的职责，公司生产经营情况正常。 点评：在资本市场，公司管理层的稳定性是投资者关注的关键因素之一，尤其董事长作为核心人物，其 解除留置并恢复正常履职，消除了此前因留置措施带来的不确定性，有助于增强投资者对公司未来发展 的信心。 NO.2 富时中国A50指数纳入百济神州等A股 点评：本事件将拓 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的枸橼酸莫沙必利片《药品注册证书》，现 将相关情况公告如下： 证券代码：603538 证券简称：美诺华 公告编号：2025-097 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于全资子公司获得枸橼酸莫沙必利片 药品注册证书的公告 药品适应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎） 引起的消化道症状，包括烧心、嗳气、恶心、呕吐、早饱、上腹胀、上腹痛等。 国产药品注册的申请并获得受理。截至本公告日，公司已投入研发费用为人民币 由于医药产品的行业特点，该药品未来销售情况可能受到政策变化、市场需 求、同类型药品市场竞争等多种不确定因素影响，具有较大不确定性，敬请广大 投资者注意投资风险。 特此公告。 一、药品相关信息 宁波美诺华药业股份有限公司 本品符合药品注册的有关要求 ...

证券日报网讯 9月3日晚间，美诺华发布公告称，公司全资子公司宁波美诺华天康药业有限公司于近日 收到国家药品监督管理局核准签发的枸橼酸莫沙必利片《药品注册证书》。 （文章来源：证券日报） ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

格隆汇9月3日丨美诺华（维权）(603538.SH)公布，全资子公司宁波美诺华天康药业有限公司（简称"美 诺华天康"）于近日收到国家药品监督管理局核准签发的枸橼酸莫沙必利片《药品注册证书》，药品适 应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎）引起的消化道症状，包括烧心、嗳 气、恶心、呕吐、早饱、上腹胀、上腹痛等。 ...

智通财经APP讯，美诺华(603538.SH)公告，公司全资子公司宁波美诺华天康药业有限公司("美诺华天 康")于近日收到国家药品监督管理局核准签发的枸橼酸莫沙必利片《药品注册证书》，该药品适应症 为：用于改善因胃肠动力减弱(如：功能性消化不良、慢性胃炎)引起的消化道症状，包括烧心、嗳气、 恶心、呕吐、早饱、上腹胀、上腹痛等。 ...